CD40LG and cardiovascular disorder: Currently, three GPIIb-IIIa antagonists (abciximab, tirofiban and eptifibatide) are approved for clinical use for the treatment of thrombotic complications, and several reports indicate that these drugs are efficient at inhibiting the release of sCD40L from platelets in patients with various forms of cardiovascular disease [61,65,66].